Analysis of Post-Liver Transplant Hepatitis C Virus Recurrence Using Serial Cluster of Differentiation Antibody Microarrays

被引:7
|
作者
Rahman, Wassim [1 ]
Tu, Thomas [2 ]
Budzinska, Magdalena [2 ]
Huang, Pauline [3 ,4 ]
Belov, Larissa [3 ,4 ]
Chrisp, Jeremy S. [3 ]
Christopherson, Richard I. [4 ]
Warner, Fiona J. [2 ]
Bowden, D. Scott [5 ]
Thompson, Alexander J. [5 ]
Bowen, David G. [1 ,2 ]
Strasser, Simone I. [1 ]
Koorey, David [1 ]
Sharland, Alexandra F. [6 ]
Yang, Jean Y. H. [7 ]
McCaughan, Geoffrey W. [1 ,2 ]
Shackel, Nicholas A. [1 ,2 ]
机构
[1] Royal Prince Alfred Hosp, AW Morrow Gastroenterol & Liver Ctr, Camperdown, NSW 2050, Australia
[2] Centenary Inst, Sydney, NSW, Australia
[3] Medsa Pty Ltd, Natl Innovat Ctr, Eveleigh, NSW, Australia
[4] Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia
[5] Victorian Infect Dis Reference Lab, Melbourne, Vic, Australia
[6] Univ Sydney, Bosch Inst, Collaborat Transplantat Res Grp, Sydney, NSW 2006, Australia
[7] Univ Sydney, Sch Math & Stat, Sydney, NSW 2006, Australia
关键词
NATURAL-HISTORY; DONOR AGE; T-CELL; FIBROSIS PROGRESSION; ANTIVIRAL THERAPY; PERIPHERAL-BLOOD; ACUTE REJECTION; INFECTION; RECIPIENTS; IMPACT;
D O I
10.1097/TP.0000000000000617
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Hepatitis C virus (HCV) reinfection of the liver allograft after transplantation is universal, with some individuals suffering severe disease recurrence. Predictive markers of recurrent disease severity are urgently needed. In this study, we used a cluster of differentiation (CD) microarray to predict the severity of HCV recurrence after transplantation. Methods. The CD antibody microarray assays of live leukocytes were performed on peripheral blood taken in the first year after transplantation. The results were grouped into phases defined as; Pre-transplant (day 0), Early (day 3 to week 2), Mid (week 4 to week 10), and Late (week 12 to week 26). Hepatitis C virus severity was based on fibrosis stages in the first 2 years (F0-1 mild and F2-4 severe). Results. Serial blood samples from 16 patients were taken before and after liver transplantation. A total of 98 assays were performed. Follow-up was 3 years or longer. Comparing recurrence severity, significantly greater numbers of CD antigens were differentially expressed on the pretransplant samples compared to any posttransplant timepoints. Five differentially expressed CD antigens before transplantation (CD27 PH, CD182, CD260, CD41, and CD34) were significantly expressed comparing severe to mild recurrence, whereas expression of only CD152 was significant in the late phase after transplantation. No relationship was observed between the donor or recipient interleukin-28B genotypes and HCV recurrence severity. Conclusions. This study shows that circulating leukocyte CD antigen expression has utility in assessing recurrent HCV disease severity after liver transplantation and serves as a proof of principle. Importantly, pretransplant CD antigen expression is most predictive of disease outcome.
引用
收藏
页码:E120 / E126
页数:7
相关论文
共 50 条
  • [1] Management of Post-Liver Transplant Recurrence of Hepatitis C
    Taylor, Justin
    Cox-North, Paula
    Landis, Charles S.
    DRUGS, 2016, 76 (18) : 1711 - 1717
  • [2] Management of Post-Liver Transplant Recurrence of Hepatitis C
    Justin Taylor
    Paula Cox-North
    Charles S. Landis
    Drugs, 2016, 76 : 1711 - 1717
  • [3] Post-liver transplant hepatitis C virus recurrence: An unresolved thorny problem
    Alberto Grassi
    Giorgio Ballardini
    World Journal of Gastroenterology, 2014, (32) : 11095 - 11115
  • [4] Post-liver transplant hepatitis C virus recurrence: An unresolved thorny problem
    Grassi, Alberto
    Ballardini, Giorgio
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (32) : 11095 - 11115
  • [5] Immunohistochemical perforin staining allows differentiation between hepatitis C recurrence and rejection post-liver transplant
    Quaglia, Alberto
    Hussain, Munther
    Henegan, Michael
    Portmann, Bernard
    Vergani, Diego
    HEPATOLOGY, 2006, 44 (04) : 480A - 480A
  • [6] Analysis of Hepatitis C Liver Transplant Outcomes Using a Cluster of Differentiation Antibody Array.
    Rahman, Wassim
    Budzinska, Magdalena
    Huang, Pauline
    Bowen, David
    Strasser, Simone
    Koorey, David
    McCaughan, Geoffrey W.
    Yang, Jean H.
    Shackel, Nicholas A.
    LIVER TRANSPLANTATION, 2013, 19 : S122 - S122
  • [7] ANALYSIS OF HEPATITIS C LIVER TRANSPLANT OUTCOMES USING A CLUSTER OF DIFFERENTIATION (CD) ANTIBODY ARRAY
    Nicholas, Shackel
    Wassim, Rahman
    Magdelina, Budzinska
    Pauline, Huang
    Larissa, Belov
    Jeremy, Chrisp
    Richard, Christopherson
    Fiona, Warner
    David, Bowen
    Simone, Strasser
    David, Koorey
    Alexandra, Sharland
    Jean, Yang
    Geoffrey, McCaughan
    IMMUNOLOGY AND CELL BIOLOGY, 2013, 91 (08): : A24 - A25
  • [8] Impact of Liver Fibrosis in Patients with Post-Liver Transplant Hepatitis C Recurrence.
    Gallegos-Orozco, Juan F.
    Yosephy, Amir
    Noble, Brie
    De Patris, Giovanni
    Aqel, Bashar A.
    Byrne, Thomas J.
    Carey, Elizabeth J.
    Douglas, David D.
    Reddy, Kunam S.
    Rakela, Jorge
    Vargas, Hugo E.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 377 - 377
  • [9] Finding a Way: Hepatitis C Virus Recurrence in a Post-Liver Transplant Patient With Multiple Treatment Failures
    Harvey, Amie
    Speziale, Alissa G.
    Frenette, Catherine
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S1284 - S1284
  • [10] Post-Liver Transplant Management of Hepatitis C
    Tien Dong
    Helen S. Te
    Current Hepatology Reports, 2016, 15 (3) : 167 - 177